Front. Cardiovasc. Med. Frontiers in Cardiovascular Medicine Front. Cardiovasc. Med. 2297-055X Frontiers Media S.A. 10.3389/fcvm.2022.1076420 Cardiovascular Medicine Correction Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants Chen Hongjie 1 Chen Jiepeng 2 Zhang Fuping 3 Li Yuanhui 4 Wang Ronghua 2 Zheng Qiang 2 Zhang Xu 2 Zeng Jun 2 Xu Feng 5 * Lin Yiguang 1 6 7 * 1Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 2Sungen Bioscience Co. Ltd., Shantou, China 3Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China 4Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China 5Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China 6The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China 7School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia

Edited and reviewed by: Baohui Xu, Stanford University, United States

 *Correspondence: Yiguang Lin Yiguang.lin@hotmail.com Feng Xu 13840157712@163.com

This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine

 05 12 2022 2022 9 1076420 21 10 2022 07 11 2022 Copyright © 2022 Chen, Chen, Zhang, Li, Wang, Zheng, Zhang, Zeng, Xu and Lin. 2022 Chen, Chen, Zhang, Li, Wang, Zheng, Zhang, Zeng, Xu and Lin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants by Chen, H., Chen, J., Zhang, F., Li, Y., Wang, R., Zheng, Q., Zhang, X., Zeng, J., Xu, F., and Lin, Y. (2022). Front. Cardiovasc. Med. 9:964977. doi: 10.3389/fcvm.2022.964977 nattokinase atherosclerosis hyperlipidaemia anti-atherogenic drug lipid lowering effect retrospective study lipid lowering agent Nattokinase (NK)

In the published article, there was an error in Table 1 Baseline characteristics of the participants as published.

Baseline characteristics of the participants.

Age (year) 67.5 (63–85)
Gender
Male 491
Female 571
Exercise
<5,000 steps/d 356
>5,000 steps/d 706
BMI
<27.5 980
>27.5 82
Smoker 259
Alcohol drinking
<100 ml/w 799
>100 ml/w 263
Vitamin K2 co-admin (180 μg/d) 181
Aspirin co-admin (100 mg/d) 96
Hyperlipidemia 1,062
Atherosclerosis 683

The corrected Table and correct format appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.